p53-mediated enhancement of radiosensitivity by selenophosphate synthetase 1 overexpression

Journal of Cellular Physiology

Volumn 209, Issue 1, 2006, Pages 131-141

  Chung, Hyun Ju ^a   Yoon, Sun Il ^a   Shin, Sun Hye ^a   Koh, Yeon A ^a   Lee, Su Jae ^a   Lee, Yun Sil ^a   Bae, Sangwoo ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SELENIUM; SELENOPHOSPHATE SYNTHETASE 1; SMALL INTERFERING RNA; SYNTHETASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER PREVENTION; CANCER THERAPY; CELL FUNCTION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IONIZING RADIATION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; SPS1 GENE;

APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HUMANS; PHOSPHOTRANSFERASES; PROTEIN-SERINE-THREONINE KINASES; RADIATION TOLERANCE; SODIUM SELENITE; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 33748283767     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20714     Document Type: Article

References (59)

1. Alsina B, Corominas M, Berry MJ, Baguna J, Serras F. 1999. Disruption of selenoprotein biosynthesis affects cell proliferation in the imaginal discs and brain of Drosophila melanogaster. J Cell Sci 112:2875-2884.
2. Bakkenist CJ, Kastan MB. 2003. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421:499-506.
3. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y. 1998. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281:1674-1677.
4. Behne D, Kyriakopoulos A. 2001. Mammalian selenium-containing proteins. Annu Rev Nutr 21:453-473.
5. Bode AM, Dong Z. 2004. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4:793-805.
6. Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM, 2004. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD.). Science 304:596-600.
7. Budhram-Mahadeo V, Morris PJ, Smith MD, Midgley CA, Boxer LM, Latchman DS. 1999. p53 suppresses the activation of the Bcl-2 promoter by the Brn-3A POU family transcription factor. J Biol Chem 274:15237-15244.
8. Clark LC, Cantor KP, Allaway WH. 1991. Selenium in forage crops and cancer mortality in U.S. counties. Arch Environ Health 46:37-42.
9. Clark LC, Combs GF, Jr., Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL, Jr., Park HK, Sanders BB, Jr., Smith CL, Taylor JR. 1996. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276: 1957-1963.
10. Combs GF, Jr., Gray WP. 1998. Chemopreventive agents: Selenium. Pharmacol Ther 79:179-192.
11. Cone JE, Del Rio RM, Davis JN, Stadtman TC. 1976. Chemical characterization of the selenoprotein component of clostridial glycine reductase: Identification of selenocysteine as the organoselenium moiety. Proc Natl Acad Sci USA 73: 2659-2663.
12. Dong Y, Ganther HE, Stewart C, Ip C. 2002. Identification of molecular targets associated with selenium-induced growth inhibition in human breast cells using cDNA microarrays. Cancer Res 62:708-714.
13. Dong Y, Zhang H, Hawthorn L, Ganther HE, Ip C. 2003. Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res 63:52-59.
14. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
15. Gaiddon C, Moorthy NC, Prives C. 1999. Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo. EMBO J 18:5609-5621.
16. Glass RS, Singh WP, Jung W, Veres Z, Scholz TD, Stadtman TC. 1993. Monoselenophosphate: Synthesis, characterization, and identity with the prokaryotic biological selenium donor, compound SePX. Biochemistry 32: 12555-12559.
17. Gudkov AV, Komarova EA. 2003. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 3:117-129.
18. Hainaut P, Mann K. 2001. Zinc binding and redox control of p53 structure and function. Antioxid Redox Signal 3:611-623.
19. Havre PA, O'Reilly S, McCormick JJ, Brash DE. 2002. Transformed and tumor-derived human cells exhibit preferential sensitivity to the thiol antioxidants, N-acetyl cysteine and penicillamine. Cancer Res 62:1443-1449.
20. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51-59.
21. Hussain SP, Amstad P, He P, Robles A, Lupold S, Kaneko I, Ichimiya M, Sengupta S, Mechanic L, Okamura S, Hofseth LJ, Moake M, Nagashima M, Forrester KS, Harris CC. 2004. p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Res 64:2350-2356.
22. Ip C. 1988. Differential effect of dietary methionine on the biopotency of selenomethionine and selenite in cancer chemoprevention. J Natl Cancer Inst 80:258-262.
23. Ip C. 1998. Lessons from basic research in selenium and cancer prevention. J Nutr 128:1845-1854.
24. Ip C, Ganther HE. 1990. Activity of methylated forms of selenium in cancer prevention. Cancer Res 50:1206-1211.
25. Ip C, Hayes C. 1989. Tissue selenium levels in selenium-supplemented rats and their relevance in mammary cancer protection. Carcinogenesis 10:921-925.
26. Ip C, Hayes C, Budnick RM, Ganther HE. 1991. Chemical form of selenium, critical metabolites, and cancer prevention. Cancer Res 51:595-600.
27. Ip C, Thompson HJ, Zhu Z, Ganther HE. 2000. In vitro and in vivo studies of methylseleninic acid: Evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 60:2882-2886.
28. Jayaraman L, Murthy KG, Zhu C, Curran T, Xanthoudakis S, Prives C. 1997. Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev 11:558-570.
29. Jiang C, Hu H, Malewicz B, Wang Z, Lu J. 2004. Selenite-induced p53 Ser-15 phosphorylation and caspase-mediated apoptosis in LNCaP human prostate cancer cells. Mol Cancer Ther 3:877-884.
30. Jonsson-Videsater K, Bjorkhem-Bergman L, Hossain A, Soderberg A, Eriksson LC, Paul C, Rosen A, Bjornstedt M. 2004. Selenite-induced apoptosis in doxorubicin-resistant cells and effects on the thioredoxin system. Biochem Pharmacol 67:513-522.
31. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. 1992. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827-830.
32. Kim IY, Veres Z, Stadtman TC. 1993. Biochemical analysis of Escherichia coli selenophosphate synthetase mutants. Lysine 20 is essential for catalytic activity and cysteine 17/19 for 8-azido-ATP derivatization. J Biol Chem 268: 27020-27025.
33. Kohrle J, Brigelius-Flohe R, Bock A, Gartner R, Meyer O, Flohe L. 2000. Selenium in biology: Facts and medical perspectives. Biol Chem 381:849-864.
34. Liu M, Pelling JC, Ju J, Chu E, Brash DE. 1998. Antioxidant action via p53-mediated apoptosis. Cancer Res 58:1723-1729.
35. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. 1994. p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810.
36. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, Jacks T. 1995. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9:935-944.
37. Martindale JL, Holbrook NJ. 2002. Cellular response to oxidative stress: Signaling for suicide and survival. J Cell Physiol 192:1-15.
38. Miyashita T, Reed JC. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299.
39. Morey M, Corominas M, Serras F. 2003. DIAP1 suppresses ROS-induced apoptosis caused by impairment of the selD/sps1 homolog in Drosophila. J Cell Sci 116:4597-4604.
40. Neve J. 1996. Selenium as a risk factor for cardiovascular diseases. J Cardiovasc Risk 3:42-47.
41. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ, Jr., Kohn KW. 1997. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300.
42. Park SH, Lee SJ, Chung HY, Kim TH, Cho CK, Yoo SY, Lee YS. 2000. Inducible heat-shock protein 70 is involved in the radioadaptive response. Radiat Res 153:318-326.
43. Park MT, Choi JA, Kim MJ, Um HD, Bae S, Kang CM, Cho CK, Kang S, Chung HY, Lee YS, Lee SJ. 2003. Suppression of extracellular signal-related kinase and activation of p38 MAPK are two critical events leading to caspase-8- and mitochondria-mediated cell death in phytosphingosine-treated human cancer cells. J Biol Chem 278:50624-50634.
44. Savaskan NE, Brauer AU, Kuhbacher M, Eyupoglu IY, Kyriakopoulos A, Ninnemann O, Behne D, Nitsch R. 2003. Selenium deficiency increases susceptibility to glutamate-induced excitotoxicity. FASEB J 17:112-114.
45. Seo YR, Kelley MR, Smith ML. 2002. Selenomethionine regulation of p53 by a ref1-dependent redox mechanism. Proc Natl Acad Sci USA 99:14548-14553.
46. Shieh SY, Ikeda M, Taya Y, Prives C. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334.
47. Smith ML, Lancia JK, Mercer TI, Ip C. 2004. Selenium compounds regulate p53 by common and distinctive mechanisms. Anticancer Res 24:1401-1408.
48. Spallholz JE, Boylan LM, Larsen HS. 1990. Advances in understanding selenium's role in the immune system. Ann N Y Acad Sci 587:123-139.
49. Stadtman TC. 1996. Selenocysteine. Annu Rev Biochem 65:83-100.
50. Stadtman TC. 2000. Selenium biochemistrv. Mammalian selenoenzymes. Ann N Y Acad Sci 899:399-402.
51. Stuart LD, Oehme FW. 1982. Environmental factors in bovine and porcine abortion. Vet Hum Toxicol 24:435-441.
52. Tamura T, Yamamoto S, Takahata M, Sakaguchi H, Tanaka H, Stadtman TC, Inagaki K. 2004. Selenophosphate synthetase genes from lung adenocarcinoma cells: Sps1 for recycling L-selenocysteine and Sps2 for selenite assimilation. Proc Natl Acad Sci USA 101:16162-16167.
53. Ueno M, Masutani H, Arai RJ, Yamauchi A, Hirota K, Sakai T, Inamoto T, Yamaoka Y, Yodoi J, Nikaido T. 1999. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 274:35809-35815.
54. Vadhanavikit S, Ip C, Ganther HE. 1993. Metabolites of sodium selenite and methylated selenium compounds administered at cancer chemoprevention levels in the rat. Xenobiotica 23:731-745.
55. Veres Z, Kim IY, Scholz TD, Stadtman TC. 1994. Selenophosphate synthetase. Enzyme properties and catalytic reaction. J Biol Chem 269:10597-10603.
56. Vit JP, Moustacchi E, Rosselli F. 2000. ATM protein is required for radiation-induced apoptosis and acts before mitochondrial collapse. Int J Radiat Biol 76: 841-851.
57. Vousden KH. 2000. p53: Death star. Cell 103:691-694.
58. Wang Z, Jiang C, Ganther H, Lu J. 2001. Antimitogenic and proapoptotic activities of methylseleninic acid in vascular endothelial cells and associated effects on PI3K-AKT, ERK, JNK and p38 MAPK signaling. Cancer Res 61: 7171-7178.
59. Wei Y, Cao X, Ou Y, Lu J, Xing C, Zheng R. 2001. SeO(2) induces apoptosis with downregulation of Bcl-2 and up-regulation of P53 expression in both immortal human hepatic cell line and hepatoma cell line. Mutat Res 490:113-121.